Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Publication

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Journal Paper/Review - Jan 1, 2016

Diem Stefan, Goldinger Simone M, Urner-Bloch Ursula, Siano Marco, Dummer Reinhard, Speiser Daniel E, Maillard Samia A, Rüesch Reinhard, Keller Fabienne, Flatz Lukas

Citation

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.

Type

Journal Paper/Review (English)

Journal

J Immunother 2016; 39

Publication Date

Jan 1, 2016

Issn Electronic

1537-4513

Pages

379-382

Brief description/objective

UNASSIGNED
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.